Search Results 1811-1820 of 19534 for hemoglobin

  1. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer - Mayo Clinic

    Hemoglobin 9.0 g/dL;; Serum creatinine 1.5 x ULN or creatinine clearance (CrCl) 30 mL/min (using the Cockcroft-Gault formula):. Female CrCl = (140 - age in ...

  2. Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT) - Mayo Clinic

    Diagnosed reduced lung function with either diffusion capacity (corrected for hemoglobin) or forced expiratory volume in 1 second (FEV1) ≤65% of predicted ...

  3. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  4. BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA) - Mayo Clinic

    Hemoglobin > 9 g/dL;; Absolute neutrophil count ≥ 1,500/mcL;; Platelets ≥ 100,000/mcL;; Total bilirubin ≤ 2 × institutional upper limit of normal (ULN);; AST ...

  5. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  6. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  7. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

    * Diffusing Capacity (of Lung) for Carbon Monoxide (DLCO) >=25% of predicted normal corrected for hemoglobin (Hb). * Prebronchodilator Forced Expiratory ...

  8. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL - Mayo Clinic

    Adequate hematology (Hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 ´ 109/L, platelets ≥100 x 109/L) without ongoing transfusional support; Adequate renal and liver ...

  9. A Study to Evaluate Ribociclib Plus Letrozole to Treat Cancer of the Ovary, Fallopian Tube or Peritoneum - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL;; Potassium, total calcium (corrected for serum albumin), magnesium, sodium and phosphorus within normal limits for the institution or ...

  10. Vinorelbine Tartrate and Cyclophosphamide in Combination with Bevacizumab or Temsirolimus in Treating Patients with Recurrent or Refractory Rhabdomyosarcoma - Mayo Clinic

    Hemoglobin ≥ 8.0 g/dL (may receive packed red blood cells [PRBC] transfusions); Bone marrow disease involvement of tumor is allowed, however, peripheral ...